Role of Low Molecular Weight Heparin in the Management of Acute Pancreatitis ??? A Prospective Study in a Tertiary Care Hospital, Tirupati

Author(s): Venkata Prakash Gandikota1, Srikanth Reddy Challapalli2, Keerthinmayee Karimaddela3, Anupama Chinni4

Acute pancreatitis (AP) runs a moderately severe and severe course in around 20
% - 30 % of cases. It can progress into severe acute pancreatitis (SAP) and
pancreatic necrosis if not appropriately intervened. This study aims to study the
effect of low molecular weight heparin in treating acute pancreatitis.
This was a prospective hospital-based study. Patients presenting to the emergency
ward in our hospital with acute pancreatitis features with a duration of 72 hours
or less and fulfilling the inclusion and exclusion criteria were included. They were
randomly divided into those receiving standard care alone, and standard care low
molecular weight heparin in addition to routine management, and results were
calculated using the chi-square test.
The number of patients in the present study was 100. The most common age
group affected was 30 - 40 years. Out of 100, 94 were male patients, and 6 were
female patients. There is no notable difference in the mean age group between
the groups. The recovery percentage is 98 % in patients with low molecular weight
heparin. The recovery rate is 86 % in patients without low molecular weight
heparin. The mortality rate is 2 % in patients with low molecular weight heparin.
The mortality rate is 14 % in patients without low molecular weight heparin. It
was found that the low molecular weight heparin usage has brought a significant
difference in the patients. Outcome affected with acute pancreatitis had a
significant P - value of 0.02.
The low molecular weight heparin by its property of improving the micro
circulations relieves the abdominal pain, prevents the disease's further
progression, and hence reduces the duration of hospital stay, morbidity, and
mortality associated with the disease and enhances the recovery rate.